Encompass Health Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EHC research report →
Range $150 – $165
Price Chart
About the company
Encompass Health Corporation delivers a range of post-acute healthcare services across the United States, offered both in dedicated facilities and directly within patients' homes. The company's operations are divided into two primary divisions: Inpatient Rehabilitation, and Home Health and Hospice. Its Inpatient Rehabilitation division specializes in providing focused recovery treatment, available on an inpatient or outpatient basis.
- CEO
- Mark J. Tarr
- IPO
- 1986
- Employees
- 29,875
- HQ
- Birmingham, AL, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a constructive multi-month uptrend, trading above both the 50-day and 200-day moving averages. It sits near the upper end of its 52-week range, which keeps the longer-term trend intact even after a pullback from the highs.
Street sentiment stays firmly positive, with a Buy consensus and a target cluster centered around $155 to $156 versus a $154.86 consensus target. Recent revisions have mostly been target raises, including Mizuho at $155, Raymond James at $155, UBS at $165, KeyBanc at $150, and Truist at $156.
The earnings setup remains favorable after eight straight EPS beats, including a 10.9% surprise in the latest quarter. Next-year EPS is projected at 6.8873, up from a 6.25 TTM base, so shareholders should watch whether reimbursement, volume, and margin discipline keep the beat streak alive.
Recent activity is mostly noise from awards and vesting, not a clear trading signal. The only discretionary pattern is net selling, led by two officer sales on 2026-08-31, while the October director grants are automatic compensation flows rather than open-market buying.
Profitability is solid, with a 44.1% gross margin, 18.37% operating margin, and 10.17% net margin. Growth is still healthy too, with revenue up 8.9% year over year and earnings up 21.6%, while free cash flow reached $1.912 billion in fiscal 2025.
EHC stands out as a scaled inpatient rehab operator with strong cash generation and a 25.11% ROE. The valuation still looks premium for healthcare facilities at 22.65 times earnings, but the market is paying for consistency and execution.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.11B
- P/E
- 21.28
- Fwd P/E
- 21.28
- PEG
- 1.03
- P/S
- 2.13
- P/B
- 5.06
- EV/EBITDA
- 10.47
- Div Yield
- 0.57%
- Gross Margin
- 38.53%
- Op Margin
- 18.32%
- Net Margin
- 10.17%
- ROE
- 25.17%
- ROIC
- 13.75%
Latest fiscal year · YoY change
- Revenue
- $5.94B+10.5%
- Gross Profit
- $2.56B+14.9%
- Op Income
- $1.05B
- Net Income
- $566.20M+24.2%
- EPS
- $5.62+24.1%
- OCF Growth
- +17.2%
- FCF Growth
- +21.9%
- 52W High
- $143.90
- 52W Low
- $92.77
- 50D MA
- $127.91
- 200D MA
- $112.98
- Beta
- 0.60
- RSI (14)
- 50
- Avg Volume
- 994.69K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Encompass Health delivered a strong third quarter with revenue, EBITDA, and EPS all up solidly, then raised full-year 2026 guidance again on the back of strong volume, acuity, and continued capacity expansion.· October 29, 2026
- Q3 revenue rose 8.9%, adjusted EBITDA increased 15.5% to $346.6 million, and adjusted EPS increased 23.6%.
- Through 9 months, revenue was up 9.2%, adjusted EBITDA up 11.9%, and adjusted EPS up 17%.
- Management raised 2026 guidance again to $6.45 billion-$6.5 billion of revenue, $1.395 billion-$1.415 billion of adjusted EBITDA, and $6.23-$6.37 of adjusted EPS.
- Same-store and total demand remained strong, supported by 5.7% discharge growth, 4% higher net revenue per discharge, and continued acuity gains.
- The company continued to expand capacity, opening new hospitals and beds, while also emphasizing a large pipeline and further opportunities from North Carolina and small-format hospitals.
In Q3 2026, net operating revenue grew 8.9%, adjusted EBITDA increased 15.5% to $346.6 million, and adjusted EPS increased 23.6%. Revenue growth was driven by 5.7% discharge growth and a 4% increase in net revenue per discharge. Bad debt expense was 2.7%, with management calling out a billing and collection disruption after a Q2 system conversion. Through the first 9 months of 2026, revenue rose 9.2%, adjusted EBITDA increased 11.9%, and adjusted EPS was up 17%. Adjusted free cash flow for the first 9 months was $634.2 million, up 8.9% year over year. Full-year 2026 guidance was raised to net operating revenue of $6.45 billion-$6.5 billion, adjusted EBITDA of $1.395 billion-$1.415 billion, and adjusted EPS of $6.23-$6.37. Management now expects 2026 net provider tax contribution to adjusted EBITDA of about $3 million, bad debt to normalize in Q4 to the historical 2% to 2.5% range, and net preopening and ramp-up costs of $20 million to $24 million.
Mark Tarr said the quarter reflected strong operating execution and patient outcomes, highlighting that growth came alongside quality metrics that continued to beat industry averages. He emphasized the strategic focus on adding capacity through new hospitals, bed additions, and small-format facilities, calling demand for inpatient rehabilitation strong and growing. He also pointed to recognition from Newsweek and NRC Health, and to the continued importance of stroke care and other high-acuity patients in the company’s mix.
Douglas Coltharp focused on the drivers of the quarter and the updated financial outlook. He said Q3 revenue growth came from discharge growth and higher net revenue per discharge, while adjusted EBITDA benefited even after a year-over-year decline in net provider tax contribution; because Florida’s fiscal 2026 program remains pending, he now expects 2026 net provider tax contribution to adjusted EBITDA of about $3 million, down from prior expectations. He also said bad debt should normalize in Q4 after a one-time system conversion issue, and noted strong liquidity with net leverage of 1.8x and about $870 million available on the revolver. Share repurchases totaled about 495,000 shares for $57.9 million in Q3 and $203.7 million year to date.
Analysts focused on 2027 setup, capacity constraints, managed care pricing, small-format hospitals, RCD expansion, bad debt, and capital allocation. Management said 2027 should be another solid year, helped by no repeat of 2026 provider tax adjustments, continued capacity additions, and ongoing strength in VA, Medicare Advantage admit-and-appeal results, and hiring. On RCD, management emphasized administrative uncertainty with Palmetto but said it believes its patients and documentation are appropriate and expects any impact to be contained, while on small-format hospitals it said one is expected to open in late 2027 and that permitting/licensing has slowed the rollout more than the company would like. On bad debt, management tied the Q3 increase to a system conversion backlog and said the queue should be cleared by year-end.
The call suggested broad operational momentum: volume, acuity, pricing, and quality all improved, and management raised full-year guidance again. The company also sees multiple growth levers ahead, including new hospital openings, bed additions, North Carolina development, and expanding pilot programs for Medicare Advantage appeals and VA volume.
Management acknowledged several moving parts that could create volatility, including unresolved Florida supplemental payment approvals, the administrative burden of expanded RCD reviews, and the fact that some 2026 margin benefits may not repeat in 2027. It also flagged that pricing comparisons will get tougher as it laps prior acuity and reimbursement gains, and that small-format hospital rollout is being slowed by licensing and permitting complexity.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.0%
- Shares Outstanding
- 98.12M
- Float Shares
- 97.13M
of shares held by institutions
619 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for EHC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jul 22, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Mar 14, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Dec 6, 22 | Filing → |
| Peter MeijerHouse · MI03 | Sell | Feb 16, 21 | Filing → |
| Susie LeeHouse · NV03 | Sell | Aug 27, 20 | Filing → |
| Susie LeeHouse · NV03 | Buy | May 19, 20 | Filing → |
| Susie LeeHouse · NV03 | Sell | Jul 31, 19 | Filing → |
| Susie LeeHouse · NV03 | Buy | Mar 15, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 10.45M | ▼ 31.10K |
| Vanguard Group Inc | 10.13M | ▼ 110.78K |
| Price T Rowe Associates Inc | 5.50M | ▲ 442.99K |
| Vanguard Portfolio Management LLC | 4.90M | ▼ 26.88K |
| Vanguard Capital Management LLC | 4.42M | ▼ 57.80K |
| State Street Corp | 3.19M | ▲ 5.05K |
| Fuller & Thaler Asset Management, Inc. | 2.72M | ▲ 260.57K |
| Citadel Advisors LLC | 2.55M | ▼ 8.40K |
| Dimensional Fund Advisors LP | 1.92M | ▲ 179.26K |
| Alliancebernstein L.P. | 1.89M | ▼ 580.20K |
| Wellington Management Group Llp | 1.88M | ▼ 1.40M |
| Geode Capital Management, LLC | 1.85M | ▼ 43.74K |
Held by 570 ETFs
Biggest fund positions in EHC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | CARMICHAEL GREG D | other | 28 |
| Oct 15, 26 | Williams Terrance | other | 28 |
| Oct 15, 26 | SCHLICHTING NANCY M | other | 38 |
| Oct 15, 26 | HERMAN JOAN E | other | 81 |
| Oct 19, 26 | Christie Edward M III | other | 221 |
| Oct 15, 26 | Christie Edward M III | other | 11 |
| Oct 19, 26 | Reidy Christopher R | other | 284 |
| Oct 15, 26 | Reidy Christopher R | other | 20 |
| Oct 15, 26 | Hayes Cain A | other | 4 |
| Oct 15, 26 | O'Connor Kevin J. | other | 18 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EHC coverage
Recent articles, reports, and earnings notes.

Encompass Health (EHC): Growth Runway Meets Leverage Risk
Encompass Health posted strong Q2 growth, raised 2026 guidance, and continues to expand capacity across its inpatient rehab network. The stock looks attractive for medium-term investors, though leverage and payer risk keep it from being a low-risk story.

Encompass Health Corporation (EHC) jumps 15% on Q3 beat
Encompass Health Corporation (EHC) jumps after-hours following a strong Q3 earnings beat and a raised full-year outlook. Revenue and adjusted EPS both topped estimates, while management lifted 2026 guidance, signaling improving fundamentals and supporting the stock’s sharp move higher.

Ensign’s short-report selloff is testing whether execution still beats the narrative
The short-report hit on Ensign is serious, but the selloff is running into a business that just posted record occupancy, 21.7% adjusted EPS growth, and higher full-year guidance. We see this as a test of whether allegations can overpower a long-running execution story, and right now execution still has the better numbers.
Want a deeper read on EHC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Why Encompass Health (EHC) is a Top Value Stock for the Long-Term
zacks.com · Nov 18
Encompass Health Stock Rallies 34% YTD: Is There More Upside Ahead?
zacks.com · Nov 17
TimesSquare Global Concentrated Small Cap Q3 2026 Portfolio Activity
seekingalpha.com · Nov 17
Encompass Health (EHC) is a Top-Ranked Momentum Stock: Should You Buy?
zacks.com · Nov 12
Should Value Investors Buy Encompass Health (EHC) Stock?
zacks.com · Nov 9
Encompass Health announces indefinite closure of Sea Pines Rehabilitation Hospital due to flood damage
prnewswire.com · Nov 6
Encompass Health Corporation (EHC) – What Are Analysts Thinking About This Stock?
defenseworld.net · Nov 6
Encompass Health (EHC) Is Up 9.52% in One Week: What You Should Know
zacks.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice